Enveric Biosciences Inc vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Enveric Biosciences Inc trades at $1.35 (market cap $5.32M), while iShares 1 3 Year Treasury Bond ETF trades at $81.98. The key difference: iShares 1 3 Year Treasury Bond ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SHY | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Fixed Income |
52-Week High | $17.40 | $83.18 |
52-Week Low | $1.28 | $81.79 |
Enterprise Value | $408.82K | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SHY, a US stock, trades at $81.985 with a slight 0.07% daily gain. Technical indicators show a mixed but overall bullish signal, with moving averages bearish and oscillators neutral. Recent corporate actions include consistent dividend payments of $0.24. The stock's financial ratios are unavailable in the provided data, limiting fundamental analysis. Market sentiment is influenced by broader bond market trends and Federal Reserve policy expectations, as highlighted in recent financial news.
The outlook for SHY is cautious due to limited fundamental data and reliance on macroeconomic factors. Investment opportunities may arise from steady dividend yields, but risks include interest rate volatility and economic uncertainty. Investors should seek updated financials for a comprehensive view, as current analysis hinges on technical signals and external market conditions rather than company-specific performance.
Trailing returns across standard periods
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →